Pacira Pharmaceuticals

GQ Bio Therapeutics is a biotechnology company focused on gene therapy and drug development, specifically targeting osteoarthritis. The company has developed a high-capacity gene therapy vector platform that employs next-generation gene transfer vehicles to deliver large and multiple genes effectively using a single vector. This innovative approach aims to enhance gene delivery efficiency, ultimately improving patient mobility and quality of life. Through its advanced gene therapy methods, GQ Bio Therapeutics seeks to address the challenges associated with treating osteoarthritis, offering new hope for affected individuals.

Spine BioPharma develops non-surgical therapies for back pain and degenerative spine diseases, aiming to reduce pain, restore function, and slow or stop disease progression. Its lead candidate targets degenerative disc disease, seeking clinical benefits of pain relief, functional restoration, and potential prevention of disease progression, enabling individuals with chronic spine conditions to improve their quality of life. The company emphasizes opioid-free, safe and effective therapies that address pain and inflammation.

Spine BioPharma develops non-surgical therapies for back pain and degenerative spine diseases, aiming to reduce pain, restore function, and slow or stop disease progression. Its lead candidate targets degenerative disc disease, seeking clinical benefits of pain relief, functional restoration, and potential prevention of disease progression, enabling individuals with chronic spine conditions to improve their quality of life. The company emphasizes opioid-free, safe and effective therapies that address pain and inflammation.

Genascence is a clinical-stage biotechnology company developing gene therapies for musculoskeletal diseases. Its work targets osteoarthritis, aiming to treat the condition, alleviate symptoms, and slow structural disease progression to improve patient outcomes. The company also pursues genetic therapies for rare disorders and other prevalent diseases, with the goal of delivering safer and more effective treatment options for affected individuals.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Flexion Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for managing musculoskeletal conditions. Its flagship product, ZILRETTA, is an intra-articular injection used for knee osteoarthritis pain management in the United States.

Spine BioPharma develops non-surgical therapies for back pain and degenerative spine diseases, aiming to reduce pain, restore function, and slow or stop disease progression. Its lead candidate targets degenerative disc disease, seeking clinical benefits of pain relief, functional restoration, and potential prevention of disease progression, enabling individuals with chronic spine conditions to improve their quality of life. The company emphasizes opioid-free, safe and effective therapies that address pain and inflammation.

Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.

Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.

Avalon.AI is a New York-based company that specializes in artificial intelligence-driven enterprise software and data analytics solutions. Its offerings are designed to support a variety of sectors, including business, government, education, and healthcare. The company provides real-time data analysis, utilizing multiple data sources to create hyper-local heat maps that identify areas impacted by pandemics, such as the Coronavirus. Avalon.AI's solutions encompass user experience enhancements, chatbots, mobile applications, and two-way communication systems, along with key user indicators and community awareness tools. By delivering actionable insights, Avalon.AI enables organizations to make informed decisions and respond effectively to emerging challenges.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

TELA Bio is a medical technology company specializing in soft tissue reconstruction. It designs, develops, and markets the OviTex Reinforced Tissue Matrix portfolio for hernia repair and abdominal wall reconstruction, as well as OviTex PR Reinforced Tissue Matrix for plastic and reconstructive surgery and OviTex for laparoscopic and robotic procedures. The reinforced matrices are derived from ovine rumen with polypropylene fiber and are intended to address unmet needs in soft tissue repair while emphasizing preservation of anatomy and minimizing long-term exposure to permanent synthetic materials. The company markets its products through a single direct sales force, principally in the United States. Founded in 2012 and headquartered in Malvern, Pennsylvania.